Breast Cancer Clinical Trial
Official title:
Development and Evaluation of Different Versions of the Decision Board for Early Breast Cancer
| Verified date | June 2007 |
| Source | Ontario Clinical Oncology Group (OCOG) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Canada: Health Canada |
| Study type | Interventional |
To enhance information transfer and decision making for women with breast cancer.
| Status | Completed |
| Enrollment | 300 |
| Est. completion date | November 2006 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: Chemotherapy Group: - Female - Histologically documented invasive carcinoma of the breast treated with modified radical mastectomy or lumpectomy - Axillary node dissection - Chemotherapy alone or in addition to tamoxifen as an appropriate treatment option Surgery Group: - Female - Newly diagnosed carcinoma of the breast diagnosed either by cytology or pathological examination, OR if no biopsy, a strong clinical suspicion of malignancy - Clinical stage I or II disease - Candidate for breast conserving surgery Exclusion Criteria: Chemotherapy Group: - Candidate for CEF chemotherapy - Clinical evidence of metastatic disease - Serious comorbidity that would preclude receiving chemotherapy treatment - Unable to speak or read English fluently (including visual impairment) - Mentally incompetent including any psychiatric or addictive disorders that would preclude shared decision-making Surgery Group: - Previous surgery for breast cancer - Previous breast irradiation - Pregnant - Clinical suspicion of bilateral breast cancer - Serious comorbidity that would preclude definitive surgery - Unable to speak or read English fluently (including visual impairment) - Mentally incompetent including any psychiatric or addictive disorder that would preclude shared decision making |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
| Country | Name | City | State |
|---|---|---|---|
| Canada | Denise Schnider | Brantford | Ontario |
| Canada | Ken Reed | Guelph | Ontario |
| Canada | Barbara Heller | Hamilton | Ontario |
| Canada | Juravinski Cancer Centre | Hamilton | Ontario |
| Canada | Ken Sanders | Hamilton | Ontario |
| Canada | Susan Reid | Hamilton | Ontario |
| Canada | Nabih Mattar | Simcoe | Ontario |
| Canada | Anna Kobylecky | St. Catharines | Ontario |
| Canada | Peter Koziarz | Welland | Ontario |
| Lead Sponsor | Collaborator |
|---|---|
| Ontario Clinical Oncology Group (OCOG) | Supportive Cancer Care Research Unit, U.S. Army Medical Research and Materiel Command |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Patient comprehension | |||
| Primary | Patient satisfaction with information transfer | |||
| Secondary | Patient satisfaction with decision making | |||
| Secondary | Physician satisfaction with information transfer | |||
| Secondary | Physician satisfaction with decision making | |||
| Secondary | Time required for administration of the instrument | |||
| Secondary | Patient preference for decision making |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |